Dr. Feldman on Adding Etoposide to Brentuximab Vedotin/CHP in Peripheral T-Cell Lymphomas

Partner | Cancer Centers | <b>John Theurer Cancer Center</b>

Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.

Tatyana Feldman, MD, hematologist and medical oncologist, John Theurer Cancer Center, discusses the efficacy of adding etoposide to brentuximab vedotin (Adcetris) plus CHP (cyclophosphamide, doxorubicin, and prednisone) followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas (PTCL).

Data from the multicenter, phase 2 trial (NCT03113500) were presented at the 2021 ASH Annual Meeting, which evaluated the safety and efficacy of the regimen in this patient population. Results showed that the 18-month progression-free survival (PFS) rate was 61% with this approach for all patients. The 18-month PFS rate was 81% in patients with anaplastic large cell lymphoma (ALCL), according to Feldman. The majority of patients with ALCL were ALK negative, although 3 patients were ALK positive, Feldman says. Notably, the 18-month PFS rate was 49% in patients with non-ALCL PTCLs, Feldman adds.

Additionally, patients with ALCL achieved an overall response rate (ORR) of 94% with this approach, and all responses were complete responses (CRs), Feldman notes. Patients with PTCL NOS experienced the worst responses with this regimen; the ORR was 82% and the CR rate was 55% in this population, Feldman reports. In patients with angioimmunoblastic T-cell lymphoma, the regimen induced an ORR of 94% with a CR rate of 82%, Feldman concludes.